Overview
- Clearmind Medicine, which announced the result Monday, said CMND-100 met the Phase I/IIa trial’s primary safety and tolerability endpoint with no serious adverse events in the higher-dose third cohort.
- The FDA-approved, multinational study is a dose‑escalation Phase I/IIa trial that evaluates safety, tolerability, pharmacokinetics, and early signs of efficacy in people with moderate to severe alcohol use disorder.
- Following Monday’s release, the stock jumped about 100% to roughly $1.44, according to Benzinga Pro data cited in market coverage.
- An independent safety board allowed the trial to continue after reviewing accumulated data, and 18 participants had completed treatment and follow-up at the time of the latest report, Blockonomi noted.
- The next milestone will be evidence that the drug reduces harmful drinking, and its non-hallucinogenic design could make treatment more acceptable to patients who want to avoid psychedelic effects.